TABLE 3.
Combination therapy for RAS‐mutated malignancies in clinical trials
| Drug | Study phase | Disease setting | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|
| Combinations of KRAS G12C allele‐specific inhibitors | ||||
| AMG 510 trametinib | I/II | Advanced solid tumors | NCT04185883 | Recruiting |
| AMG 510 TNO155 | ||||
| AMG 510 RMC‐4630 | ||||
| AMG 510 afatinib | ||||
| AMG 510 palbociclib | ||||
| AMG 510 everolimus | ||||
| AMG 510 anti‐PD‐1/PD‐L1 antibodies | ||||
| MRTX849 afatinib | I/II | Advanced solid tumors | NCT03785249 | Recruiting |
| MRTX849 TNO155 | I/II | Advanced solid tumors | NCT04330664 | Active, not recruiting |
| MTRX849 anti‐PD‐1 antibody | II | NSCLC | NCT04613596 | Recruiting |
| MRTX849 cetuximab | III | CRC | NCT04793958 | Recruiting |
| MTRX849 BI‐1701963 | I | Advanced solid tumors | NCT04975256 | Recruiting |
| MRTX849 palbociclib | I | Advanced solid tumors | NCT05178888 | Recruiting |
| GDC‐6036 cetuximab | I | Advanced solid tumors | NCT04449874 | Recruiting |
| GDC‐6036 bevacizumab | ||||
| GDC‐6036 erlotinib | ||||
| GDC‐6036 anti‐PD‐L1 antibody | ||||
| Combinations of MAPK pathway inhibitors | ||||
| Lifirafenib mirdametinib | I/II | Advanced solid tumors | NCT03905148 | Recruiting |
| Cobimetinib GDC‐0994 | I | Advanced solid tumors | NCT02457793 | Completed |
| Combinations of MAPK and PI3K pathway inhibitors | ||||
| Selumetinib MK2206 | I | PDAC | NCT01658943 | Completed |
| Trametinib GSK2141795 | II | Melanoma | NCT01941927 | Completed |
| Trametinib everolimus | I | Advanced solid tumors | NCT00955773 | Completed |
| Pimasertib voxtalisib | I | Advanced solid tumors | NCT01390818 | Completed |
Abbreviations: PD‐1, programmed cell death protein 1; PD‐L1, programmed cell death protein‐ligand 1; PDAC, pancreatic ductal adenocarcinoma; CRC, colorectal cancer; NSCLC, non‐small cell lung cancer; MAPK, mitogen‐activated protein kinase; PI3K, phosphoinositide 3‐kinases